Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage immunology company headquartered in San Francisco, California, dedicated to discovering and developing therapeutic products to treat and prevent serious infectious diseases and cancer. The company's mission is to power the immune system to transform lives, striving for a world free from infectious diseases.

Leveraging deep immunological insights and cutting-edge technologies, Vir Biotechnology's pipeline is built on a next-generation antibody platform and the PRO-XTEN® protease-releasable masking technology. The company focuses on therapeutic areas including chronic hepatitis delta (HDV), HIV, and oncology, particularly solid tumors like prostate cancer. Its development pipeline features investigational therapies such as Tobevibart + elebsiran for HDV, preclinical antibody candidates for HIV, and VIR-5500, VIR-5818, and VIR-5525 for various solid tumors. Vir has also contributed to therapies for global health challenges like COVID-19 and Ebola.

Under the leadership of President and CEO Marianne De Backer, who assumed the CEO role in April 2023 and President in March 2026, Vir Biotechnology has recently expanded its strategic focus. In February 2026, the company announced a global strategic collaboration with Astellas Pharma, valued at up to $1.7 billion, to advance VIR-5500 for prostate cancer, diversifying its pipeline and extending its cash runway. Additionally, a licensing agreement with Norgine was signed in December 2025 for its hepatitis delta program. The company maintains a strong financial position, with approximately $781.6 million in cash and investments as of December 31, 2025, providing runway into late 2027 or mid-2028. Key upcoming catalysts include data readouts for its oncology and hepatitis delta programs in 2026 and early 2027.